Abstract
Background. The standard therapy for a patient with metastatic or recurrent soft tissue sarcoma is systemic chemotherapy. However, a sarcoma is less sensitive to cytotoxic chemotherapeutic agents. In Japan, pazopanib is the first approved oral multitargeted tyrosine kinase inhibitor for soft tissue sarcoma. We herein report a patient who experienced a long-term therapeutic effect with pazopanib treatment. Case. A 77-year-old man with recurrent fibrosarcoma of the right chest wall underwent systemic chemotherapy with doxorubicin. However, after the treatment was discontinued, the tumor size increased and he developed grade 4 neutropenia. Thereafter, second-line treatment with pazopanib was initiated. The tumor size decreased and the patient continued the pazopanib treatment for seven months without experiencing severe adverse effects or a dose reduction. We were able to continue the pazopanib therapy without a dose reduction for seven months until the enlargement of the tumor. Conclusion. When it is difficult to apply cytotoxic systemic chemotherapy, pazopanib may be one of the useful therapeutic options for the treatment of fibrosarcoma.
